Concord Medical Files 2020 Annual Report on Form 20-F
Concord Medical Services Holdings Limited (NYSE: CCM) filed its annual report on Form 20-F for the fiscal year ending December 31, 2020. The report is accessible on the Company's investor relations and SEC websites. Concord Medical specializes in cancer treatment and operates an extensive network of cancer hospitals and diagnostic centers across China. Additionally, the Company has established proton therapy facilities and focuses on advanced cancer care and medical equipment services. Shareholders can request a hard copy of the report free of charge.
- Completion of the Guangzhou Concord Cancer Center construction in October 2020, expected to operate from June 2021.
- Operation of a network of 27 centers for radiotherapy and diagnostic imaging across 20 cities in China.
- None.
BEIJING, Oct. 15, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers, premium cancer hospitals, and specialty cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2020 (the "Annual Report") with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed on Concord Medical's investor relations website at http://ir.ccm.cn and on the SEC's website at www.sec.gov. Shareholders may receive a hard copy of the Annual Report free of charge upon request. Requests should be submitted to http://ir.ccm.cn.
About Concord Medical
Concord Medical Services Holdings Limited is a healthcare provider specialized in cancer treatment, research, education and prevention. The Company operates a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centres in China. The Company focuses on providing multidisciplinary cancer care approach in all areas of oncology services in its cancer hospitals. The Company is also establishing proton centers, premium cancer hospitals, and specialty cancer hospitals. In October 2020, the company completed the construction of Guangzhou Concord Cancer Center, which is expected to be in operation in June 2021. The Company also equips its hospitals with technologically advanced equipment such as the state-of-the-art proton therapy system in its Beijing, Shanghai and Guangzhou cancer hospitals. In addition, the Company saw the opportunity of the expanding market of medical equipment in China and developed its product life-cycle management services form its existing medical equipment and consumable sales services. As of December 31, 2020, the Company operated a network of 27 radiotherapy centers and diagnostic imaging centers, which are based in 20 hospitals, established under long-term lease and management services arrangements with the Company and spanning over 20 cities across 13 provinces and administrative regions in China. To ensure the commitment to the highest standard of medical services for patients, the Company offers ongoing education and training for doctors and other medical professionals in its network hospitals and centres in both domestic and overseas medical institutions. For more information, please see http://ir.ccm.cn.
View original content:https://www.prnewswire.com/news-releases/concord-medical-files-2020-annual-report-on-form-20-f-301401478.html
SOURCE Concord Medical Services Holdings Limited
FAQ
What is the purpose of Concord Medical's Form 20-F filing?
Where can I access Concord Medical's annual report for 2020?
When does Concord Medical expect the Guangzhou Concord Cancer Center to begin operations?
How many radiotherapy and diagnostic imaging centers does Concord Medical operate?
